SynthesisBMC nephrology2025
Role of hydroxychloroquine in primary glomerular disease - a systematic review and meta-analysis of the current evidence.
Synthesis in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHydroxychloroquine is increasingly being used to treat primary glomerular diseases. It has shown promising results in terms of reducing proteinuria and stabilizing kidney function. This systematic review aimed to assess the effects of HCQ on proteinuria and the estimated glomerular filtration rate (eGFR) in primary glomerular diseases and evaluate its safety profile.
methodsA literature search was conducted using PubMed, ScienceDirect, Springer, and Google Scholar for articles published between 2014 and 2024. Articles incorporating hydroxychloroquine for the treatment of primary glomerular diseases were considered. These studies evaluated the effect of HCQ on 24-hour proteinuria and eGFR. Pooled mean differences (MDs) and heterogeneity metrics (Tau², I², and Q-test) were analysed. The safety data from all included studies were reviewed.
resultsHCQ administration significantly reduced proteinuria (MD = -0.69, 95% CI= -0.79 to -0.59), with pronounced effects for longer treatment durations (MD = -0.74, 95% CI= -0.81 to -0.67), and in patients with membranous nephropathy (MD = -3.00, 95% CI= -4.46 to -1.53). Conversely, no significant improvement in eGFR was observed after HCQ treatment (MD = -1.03, 95% CI= -2.73 to - 0.67). A beneficial effect was noticed in patients with IgA nephropathy (MD = -2.65, 95% CI= -5.16 to -0.14). Moderate to substantial heterogeneity (I² = 69-95%) was observed for proteinuria outcomes, but no heterogeneity was found for eGFR outcomes (I² = 0%). 69 adverse events were reported, of which gastrointestinal and mucocutaneous effects were the most common.
conclusionHCQ therapy for primary glomerular diseases showed a trend toward reducing proteinuria without significant effects on eGFR, with a better safety profile.
trial registrationThis systematic review was registered in PROSPERO with ID CRD42024597762.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.